Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System
Our study identified potential new adverse event signals and offered a thorough understanding of aztreonam's safety profiles. This information is crucial for enhanced cliggnical monitoring and risk assessment, aiding healthcare professionals in tailoring their approach.
Authors
- Li-Mian Hong
- Hong Zhou (ORCID: https://orcid.org/0000-0002-3271-6770)
- Lili Cai (ORCID: https://orcid.org/0009-0007-2803-0788)
- Zhi-Hang Lin
- Namei Wu (ORCID: https://orcid.org/0000-0002-9328-5345)
Institutions
- Fujian Medical University (CN)
- Fuzhou Maternity and Child Health Care Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1080/14740338.2024.2430307
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.35